Filing Flows › Harvard Bioscience (HBIO) › Q4 2024
Harvard Bioscience (HBIO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 14, 2025
Harvard Bioscience (HBIO) reported revenue of $24.6M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and +12% from the quarter before. Operating margin was 0.0%, net earnings $18K (0.1% of revenue).
Harvard Bioscience, Q4 2024: revenue $24.6M (-13% year over year), operating margin 0.0%, net earnings $18K, operating cash flow $1.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.6M | +12% | -13% |
| Gross profit | $14.0M | +10% | -14% |
| Operating profit | $11K | — | -96% |
| Net earnings | $18K | — | — |
| Operating cash flow | $1.7M | — | -60% |
| Free cash flow | $1.4M | — | -59% |
What changed
Revenue was $24.6M in Q4 2024, down 13% year over year and up 12% from the previous quarter. Instruments, Equipment, Software, and Accessories was the largest line at 91% of revenue.
Gross margin was 57.1%, down 0.9 points from a year earlier. Operating profit was $11K, a 0.0% margin (down 1.0 points year over year). Operating expenses fell 13% while revenue fell 13%. Net earnings were $18K. The effective tax rate was 96.9%. Non-operating items added $579K, 98% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $1.7M (down 60% year over year), 9583% of net earnings. Non-cash charges added back $1.7M of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $1.0M. Capital expenditures of $301K left free cash flow of $1.4M.
Questions
What was Harvard Bioscience's revenue in the fourth quarter 2024?
Harvard Bioscience (HBIO) reported revenue of $24.6M for the fourth quarter 2024 (Q4 2024), -13% from a year earlier and +12% from the quarter before.
Was Harvard Bioscience profitable in the fourth quarter 2024?
Operating profit was $11K (0.0% of revenue) and net earnings $18K.
Source: Harvard Bioscience 10-K on SEC EDGAR.